Tema Obesity & Cardiometabolic ETF Rating $27.69 +0.28 (+1.02%) As of 04/17/2025 03:30 PM Eastern Add Compare Share Share Ratings Stock AnalysisChartHoldingsRatingsBuy This Stock Tema Obesity & Cardiometabolic ETF Aggregate Rating and Price Target (2025)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.HRTS Aggregate RatingModerate Buy 2.81Holdings in HRTS have an aggregate rating of Moderate Buy based on 631 analyst ratings issued in the past year covering 38 companies (84.0% of the portfolio).HRTS Aggregate Price Target$27.69High Prediction$27.69Average Prediction$27.69Low Prediction$27.69Holdings in HRTS have an aggregate price target of $27.69 and a range of $27.69 to $27.69 covering 38 companies (84.0% of the portfolio).HRTS Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy8 Buy rating(s)Moderate Buy26 Moderate Buy rating(s)Hold4 Hold rating(s)Reduce0 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by Tema Obesity & Cardiometabolic ETF Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 38 HRTS Holdings Export to ExcelWeight In ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings9.94%LLYEli Lilly and Company$841.70+14.5%4.7942 of 5 stars2.89$1,012.00 20.2%19News CoveragePositive NewsGap UpHigh Trading Volume7.17%UNHUnitedHealth Group$456.10-22.0%4.7195 of 5 stars3.13$632.85 38.8%23Earnings ReportAnalyst UpgradeNews CoverageGap DownHigh Trading Volume4.03%BBIOBridgeBio Pharma$33.87+0.1%4.5934 of 5 stars2.92$53.00 56.5%12Analyst ForecastInsider TradeAnalyst RevisionNews Coverage4.01%ABTAbbott Laboratories$131.00+1.0%4.8637 of 5 stars2.84$142.59 8.8%19Earnings ReportEx-DividendAnalyst ForecastOptions VolumeAnalyst RevisionNews CoveragePositive News3.74%RHHBYRoche$38.90+0.8%N/A2.5063.65%VRTXVertex Pharmaceuticals$489.10+0.7%4.11 of 5 stars2.64$512.41 4.8%25Short Interest ↓News CoveragePositive News3.20%GILDGilead Sciences$104.49-0.4%4.5282 of 5 stars2.72$105.12 0.6%29Upcoming EarningsInsider TradeNews CoveragePositive News3.10%MDTMedtronic$82.58-0.1%4.7174 of 5 stars2.44$96.14 16.4%16Short Interest ↓News CoveragePositive News3.06%BSXBoston Scientific$95.08-0.2%4.434 of 5 stars3.04$110.22 15.9%23Upcoming EarningsAnalyst UpgradeNews CoveragePositive News2.87%TMOThermo Fisher Scientific$426.11-2.4%4.9268 of 5 stars2.81$642.67 50.8%21Upcoming EarningsAnalyst ForecastNews CoveragePositive News2.65%MRKMerck & Co., Inc.$77.93+1.9%4.9993 of 5 stars2.64$115.50 48.2%22Upcoming EarningsAnalyst ForecastPositive News2.53%BMYBristol-Myers Squibb$49.24-0.3%4.7289 of 5 stars2.32$57.67 17.1%19Upcoming EarningsShort Interest ↓Analyst RevisionNews CoveragePositive News2.46%CRNXCrinetics Pharmaceuticals$30.42+2.8%3.5049 of 5 stars2.92$73.00 140.0%13Positive News2.27%ABBVAbbVie$172.78+0.6%4.8985 of 5 stars2.85$210.71 22.0%26Upcoming EarningsEx-DividendAnalyst ForecastAnalyst RevisionNews CoveragePositive News2.09%CYTKCytokinetics$39.48+0.8%3.8585 of 5 stars2.94$81.63 106.8%18Analyst ForecastInsider TradeNews Coverage2.06%EWEdwards Lifesciences$71.56+0.5%4.118 of 5 stars2.38$78.55 9.8%24Upcoming EarningsAnalyst RevisionNews CoveragePositive News1.99%REGNRegeneron Pharmaceuticals$563.16+2.5%4.8398 of 5 stars2.77$963.56 71.1%26Analyst ForecastNews CoveragePositive News1.93%DHRDanaher$186.71-2.1%4.9558 of 5 stars2.85$274.55 47.0%20Upcoming EarningsAnalyst ForecastShort Interest ↓News CoveragePositive News1.92%MCKMcKesson$697.22+0.4%4.5753 of 5 stars2.88$668.50 -4.1%16News CoveragePositive News1.90%PODDInsulet$246.80-1.6%4.5854 of 5 stars2.82$292.06 18.3%17Short Interest ↓Positive NewsGap Down1.87%ALNYAlnylam Pharmaceuticals$234.56+1.8%4.6297 of 5 stars2.77$315.58 34.5%26Analyst RevisionNews CoveragePositive News1.86%AMGNAmgen$277.29-1.9%4.6108 of 5 stars2.48$314.91 13.6%23Analyst DowngradeAnalyst RevisionNews CoveragePositive News1.56%ASNDAscendis Pharma A/S$165.05+4.4%2.2855 of 5 stars2.93$204.67 24.0%15Analyst ForecastNews CoveragePositive News1.47%DXCMDexCom$68.59-0.2%4.9043 of 5 stars2.95$99.00 44.3%20News CoveragePositive NewsGap Down1.28%MREOMereo BioPharma Group$2.30+8.0%1.7372 of 5 stars3.25$7.71 235.4%8High Trading Volume1.28%MDGLMadrigal Pharmaceuticals$301.66-2.0%4.4318 of 5 stars2.80$378.44 25.5%10News CoveragePositive News1.22%MASIMasimo$152.15+0.3%4.4333 of 5 stars2.83$194.80 28.0%6News CoveragePositive NewsGap Up1.11%INSMInsmed$72.53+3.3%4.0861 of 5 stars3.00$94.00 29.6%16Insider TradeNews CoveragePositive News0.83%MIRMMirum Pharmaceuticals$39.10+0.9%3.9332 of 5 stars3.09$58.20 48.8%11Analyst RevisionNews CoveragePositive News0.80%WSTWest Pharmaceutical Services$201.78-3.5%4.6275 of 5 stars2.86$332.50 64.8%7Upcoming EarningsNews CoverageHigh Trading Volume0.80%IONSIonis Pharmaceuticals$28.40+0.2%4.0399 of 5 stars2.70$56.72 99.7%20Analyst ForecastAnalyst RevisionNews Coverage0.74%AKROAkero Therapeutics$37.63+0.5%4.2284 of 5 stars3.00$76.29 102.7%9Insider TradePositive NewsGap Up0.71%VKTXViking Therapeutics$23.94+1.4%4.268 of 5 stars2.92$89.75 274.9%13Upcoming EarningsAnalyst ForecastOptions VolumeNews CoveragePositive NewsGap Down0.59%GPCRStructure Therapeutics$21.76+17.4%2.4344 of 5 stars3.00$81.29 273.6%8News CoverageGap UpHigh Trading Volume0.55%ARWRArrowhead Pharmaceuticals$11.24-1.0%3.5592 of 5 stars2.60$41.44 268.7%10News CoveragePositive News0.33%RCKTRocket Pharmaceuticals$6.33+2.9%4.6217 of 5 stars2.92$43.00 579.3%12News CoveragePositive News0.22%NTLAIntellia Therapeutics$7.23+5.4%4.3354 of 5 stars2.63$37.56 419.4%190.16%MTSRMetsera$19.57+11.5%N/A3.00$47.00 140.2%4 This page (NYSEARCA:HRTS) was last updated on 4/20/2025 by MarketBeat.com Staff From Our PartnersTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredElon Reveals Why There Soon Won’t Be Any Money For Social SecurityElon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...Colonial Metals | SponsoredTrump’s Top Secret $9 Trillion AI SuperweaponJeff Brown spotted Nvidia at $1. Now he’s revealing a new AI superweapon — and the Musk-connected stocks that ...Brownstone Research | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredClaim Your FREE Protection GuideIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | Sponsored🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tema Obesity & Cardiometabolic ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share Tema Obesity & Cardiometabolic ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
